Header Logo

Connection

BANU K ARUN to BRCA2 Protein

Back to Details
This is a "connection" page, showing publications BANU K ARUN has written about BRCA2 Protein.
BANU K ARUN
Connection Strength
7.179
BRCA2 Protein
  1. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer. 2024 May 01; 130(9):1600-1608.
    View in: PubMed
    Score: 0.769
  2. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109.
    View in: PubMed
    Score: 0.514
  3. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer. 2018 02 06; 18(1):152.
    View in: PubMed
    Score: 0.512
  4. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. Int J Oncol. 2015 Jul; 47(1):262-8.
    View in: PubMed
    Score: 0.424
  5. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J. 2015 May-Jun; 21(3):260-7.
    View in: PubMed
    Score: 0.419
  6. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol. 2010 Sep 20; 28(27):4214-20.
    View in: PubMed
    Score: 0.306
  7. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer. 2009 Feb 15; 115(4):725-30.
    View in: PubMed
    Score: 0.275
  8. High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila). 2009 Feb; 2(2):122-7.
    View in: PubMed
    Score: 0.274
  9. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer. 2006 Dec 15; 107(12):2745-51.
    View in: PubMed
    Score: 0.237
  10. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. Br J Cancer. 2024 Nov; 131(9):1400-1414.
    View in: PubMed
    Score: 0.202
  11. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open. 2024 Jun 03; 7(6):e2418486.
    View in: PubMed
    Score: 0.199
  12. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024 Mar; 200:113580.
    View in: PubMed
    Score: 0.194
  13. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Res Treat. 2022 Nov; 196(1):143-152.
    View in: PubMed
    Score: 0.176
  14. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nat Commun. 2021 02 17; 12(1):1078.
    View in: PubMed
    Score: 0.158
  15. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021 03; 146:30-47.
    View in: PubMed
    Score: 0.158
  16. Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast J. 2020 08; 26(8):1572-1582.
    View in: PubMed
    Score: 0.150
  17. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.143
  18. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. Breast J. 2019 07; 25(4):575-577.
    View in: PubMed
    Score: 0.141
  19. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. J Natl Cancer Inst. 2019 04 01; 111(4):350-364.
    View in: PubMed
    Score: 0.139
  20. Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer. J Glob Oncol. 2018 08; 4:1-9.
    View in: PubMed
    Score: 0.132
  21. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018 06; 7(6):2718-2726.
    View in: PubMed
    Score: 0.130
  22. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018 05; 39(5):593-620.
    View in: PubMed
    Score: 0.129
  23. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076.
    View in: PubMed
    Score: 0.121
  24. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 2016 Dec 06; 7(49):80465-80481.
    View in: PubMed
    Score: 0.118
  25. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2016 06; 157(2):319-327.
    View in: PubMed
    Score: 0.113
  26. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist. 2015 Jun; 20(6):593-7.
    View in: PubMed
    Score: 0.106
  27. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015 Jan 15; 121(2):269-75.
    View in: PubMed
    Score: 0.101
  28. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist. 2014 Aug; 19(8):797-804.
    View in: PubMed
    Score: 0.100
  29. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72.
    View in: PubMed
    Score: 0.099
  30. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014 04; 10(4):e1004256.
    View in: PubMed
    Score: 0.098
  31. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15; 120(10):1557-64.
    View in: PubMed
    Score: 0.097
  32. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat. 2012 May; 133(1):347-55.
    View in: PubMed
    Score: 0.084
  33. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res Treat. 2010 Nov; 124(2):441-51.
    View in: PubMed
    Score: 0.074
  34. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2024 01; 10:e2300285.
    View in: PubMed
    Score: 0.048
  35. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. Commun Biol. 2022 10 06; 5(1):1061.
    View in: PubMed
    Score: 0.044
  36. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021 09; 23(9):1726-1737.
    View in: PubMed
    Score: 0.040
  37. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
    View in: PubMed
    Score: 0.038
  38. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
    View in: PubMed
    Score: 0.030
  39. A two-stage approach to genetic risk assessment in primary care. Breast Cancer Res Treat. 2016 Jan; 155(2):375-83.
    View in: PubMed
    Score: 0.028
  40. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212.
    View in: PubMed
    Score: 0.023
  41. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. Hum Pathol. 2012 Nov; 43(11):1932-9.
    View in: PubMed
    Score: 0.022
  42. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008 Apr 14; 8:101.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.